Table 3.

Quick cytotoxicity screening using SRB for chitosan nanoparticles at concentrations of 10 mg/ml (CHNPs), pure lectins (PHA, PNA, and SBA), and their conjugates using 400 µl of 0.25% glutaraldehyde (PHA-CHNPs, PNA-CHNPs, and SBA-CHNPs) at two concentrations (10 and 100 μg/ml) against two normal cell lines (OEC and HSF). The results are expressed in terms of cell viability percentages as mean ± standard deviation

Normal cell lines	Cell viability (%)
	Concentration of conjugates (µg/ml)	CHNPs	PHA	PHA-CH NPs	PNA	PNA-CHNPs	SBA	SBA-CHNPs
OEC: oral epithelial cell	10	99.17 ± 0.87	97.97 ± 0.45	97.25 ± 0.91	98.99 ± 1.32	98.16 ± 0.53	98.06 ± 1.45	90.91 ± 0.56
	100	99.79 ± 0.59	97.05 ± 0.98	96.56 ± 0.63	96.05 ± 1.51	96.72 ± 0.43	92.58 ± 1.92	97.58 ± 1.56
HSF: human skin fibroblast	10	98.59 ± 0.72	96.02 ± 0.87	96.23 ± 0.78	98.94 ± 1.96	102.67 ± 1.97	96.82 ± 1.74	99.32 ± 0.57
	100	97.67 ± 0.53	95.58 ± 0.22	96.37 ± 0.51	102.23 ± 2.84	101.86 ± 2.89	98.46 ± 1.23	97.16 ± 0.36

CHNPs chitosan nanoparticles, PHA phytohemagglutinin lectin, PNA peanut agglutinin, SBA soybean agglutinin, PHA-CHNPs phytohemagglutinin lectin–conjugated chitosan nanoparticles, PNA-CHNPs peanut agglutinin lectin–conjugated chitosan nanoparticles, SBA-CHNPs soybean agglutinin lectin–conjugated chitosan nanoparticles